Prospector Partners LLC Has $3.61 Million Position in Pfizer Inc. $PFE

Key Takeaways:

• Prospector Partners LLC boosted its Pfizer holdings by 60.9 percent in the first quarter.
• The firm purchased an additional 53,900 Pfizer shares.
• Its total position now stands at 142,455 shares.
• The enlarged stake is valued at roughly $3.61 million.
• The figures come from first-quarter data compiled by HoldingsChannel.

A Bigger Bet on Pfizer
Prospector Partners LLC, a Connecticut-based institutional investor, has quietly expanded its position in Pfizer Inc. (NYSE: PFE). Regulatory data reviewed by HoldingsChannel show the fund added 53,900 shares during the first quarter, pushing its stake up 60.9 percent to a total of 142,455 shares.

Sizing Up the Purchase
The newly filed numbers put a dollar figure on the move: approximately $3.61 million. While the filing does not spell out the fund’s reasons, the scale of the purchase represents a notable vote of confidence in the New York Stock Exchange-listed biopharmaceutical giant.

Before and After

| Period | Shares Held | Change in Shares | Percent Change | Estimated Value* | |——–|————-|——————|—————-|——————| | Prior to Q1 Purchase | 88,555† | — | — | — | | After Q1 Purchase | 142,455 | +53,900 | +60.9 % | $3.61 million |

*Value reported by HoldingsChannel.
†Figure derived by subtracting the newly acquired shares from the current total.

Reading the Filing
HoldingsChannel, which aggregates institutional ownership data, disclosed the adjustment in Prospector Partners’ portfolio. Such filings offer a window into how professional money managers reposition their assets from quarter to quarter.

What the Numbers Suggest
With its enlarged stake, Prospector Partners is now more heavily exposed to the fortunes of Pfizer, one of the world’s largest biopharmaceutical companies. Whether the fund plans further additions remains to be seen, but the first-quarter purchase underscores the firm’s conviction—at least for now—in PFE.

(End of Article)